Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: How useful, how feasible?

Clinica Chimica Acta

Volumn 443, Issue , 2015, Pages 85-93

  Emdin, Michele ^a,b   Fatini, Cinzia ^c   Mirizzi, Gianluca ^a   Poletti, Roberta ^a,b   Borrelli, Chiara ^b   Prontera, Concetta ^a   Latini, Roberto ^d   Passino, Claudio ^a,b   Clerico, Aldo ^a,b   Vergaro, Giuseppe ^a,b  

^a Division of Cardiovascular Medicine   (Italy)

^b SCUOLA SUPERIORE SANT ANNA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Aldosterone; Angiotensin; Biomarkers; Heart failure; Renin

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; BIOLOGICAL MARKER; RENIN; ANGIOTENSIN DERIVATIVE;

ARTICLE; FEASIBILITY STUDY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEART FAILURE; HORMONE DETERMINATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; NONHUMAN; PATHOGENESIS; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; METABOLISM; REPRODUCIBILITY;

ALDOSTERONE; ANGIOTENSINS; BIOMARKERS; HEART FAILURE; HUMANS; RENIN; REPRODUCIBILITY OF RESULTS;

EID: 84924261086     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.10.031     Document Type: Article

References (104)

1. Oparil S., Haber E. The renin-angiotensin system (first of two parts). N Engl J Med 1974, 291:389-401.
2. Oparil S., Haber E. The renin-angiotensin system (second of two parts). N Engl J Med 1974, 291:446-457.
3. Sata M., Fukuda D. Crucial role of renin-angiotensin system in the pathogenesis of atherosclerosis. J Med Invest 2010, 57:12-25.
4. Unger T., Li J. The role of the renin-angiotensin-aldosterone system in heart failure. J Renin Angiotensin Aldosterone Syst 2004, 5(Suppl. 1):S7-S10.
5. Villela D., Leonhardt J., Patel N., et al. Angiotensin type 2 receptor (AT2R) and receptor Mas: a complex liaison. Clin Sci (Lond) 2015, 128:227-234.
6. Santos R.A., Simoes e Silva A.C., Maric C., et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 2003, 100:8258-8263.
7. Kim S., Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000, 52:11-34.
8. Unger T. Neurohormonal modulation in cardiovascular disease. Am Heart J 2000, 139:S2-S8.
9. Namsolleck P., Recarti C., Foulquier S., Steckelings U.M., Unger T. AT2 receptor and tissue injury: therapeutic implications. Curr Hypertens Rep 2014, 16:416.
10. Ardaillo R., Michael J.B. The relative role of circulating ad tissue renin-angiotensin-systems. Nephrol Dial Transplant 1999, 14:283-286.
11. Weir M.R., Dzau V.J. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 1999, 12:205S-213S.
12. Jankowski V., Vanholder R., van der Giet M., et al. Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol 2007, 27:297-302.
13. Jankowski V., Tölle M., Santos R.A., et al. Angioprotectin: an angiotensin II-like peptide causing vasodilatory effects. FASEB J 2011, 25:2987-2995.
14. Lautner R.Q., Villela D.C., Fraga-Silva R.A., et al. Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ Res 12 2013, 112:1104-1111.
15. Danser A.H., Schunkert H. Renin-angiotensin system gene polymorphisms: potential mechanisms for their association with cardiovascular diseases. Eur J Pharmacol 2000, 410:303-316.
16. Tsai C.T., Hwang J.J., Ritchie M.D., et al. Renin-angiotensin system gene polymorphisms and coronary artery disease in a large angiographic cohort: detection of high order gene-gene interaction. Atherosclerosis 2007, 195:172-180.
17. Jeunemaitre X., Soubrier F., Kotelevtsev Y.V., et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992, 71:169-180.
18. Schunkert H., Hense H.W., Gimenez-Roqueplo A.P., et al. The angiotensinogen T235 variant and the use of antihypertensive drugs in a population-based cohort. Hypertension 1997, 29:628-633.
19. Germain S., Bonnet F., Philippe J., Fuchs S., Corvol P., Pinet F. A novel distal enhancer confers chorionic expression on the human renin gene. J Biol Chem 1998, 273:25292-25300.
20. Fuchs S., Philippe J., Germain S., et al. Functionality of two new polymorphisms in the human renin gene enhancer region. J Hypertens 2002, 20:2391-2398.
21. Rigat B., Hubert C., Corvol P., Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 1992, 20:1433.
22. Rigat B., Hubert C., Alhenc-Gelas F., Cambien F., Corvol P., Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990, 86:1343-1346.
23. Hunley T.E., Julian B.A., Phillips J.A., et al. Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy. Kidney Int 1996, 49:571-577.
24. Rosatto N., Pontremoli R., De Ferrari G., Ravazzolo R. Intron 16 insertion of the angiotensin converting enzyme gene and transcriptional regulation. Nephrol Dial Transplant 1999, 14:868-871.
25. Suehiro T., Morita T., Inoue M., Kumon Y., Ikeda Y., Hashimoto K. Increased amount of the angiotensin-converting enzyme (ACE) mRNA originating from the ACE allele with deletion. Hum Genet 2004, 115:91-96.
26. Cuoco M.A., Pereira A.C., de Freitas H.F., et al. Angiotensin-converting enzyme gene deletion polymorphism modulation of onset of symptoms and survival rate of patients with heart failure. Int J Cardiol 2005, 99:97-103.
27. Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990, 82:1730-1736.
28. Raynolds M.V., Bristow M.R., Bush E.W., et al. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 1993, 342:1073-1075.
29. Cambien F., Poirier O., Lecerf L., et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992, 359:641-644.
30. Araújo M.A., Goulart L.R., Cordeiro E.R., et al. Genotypic interactions of renin-angiotensin system genes in myocardial infarction. Int J Cardiol 2005, 103:27-32.
31. Wang J.G., Staessen J.A. Genetic polymorphisms in the renin-angiotensin system: relevance for susceptibility to cardiovascular disease. Eur J Pharmacol Dec 27 2000, 410:289-302.
32. Feldman A.M. The emerging role of pharmacogenomics in the treatment of patients with heart failure. Ann Thorac Surg 2003, 76:S2246-S2253.
33. Sayed-Tabatabaei F.A., Oostra B.A., Isaacs A., van Duijn C.M., Witteman J.C. ACE polymorphisms. Circ Res 2006, 98:1123-1133.
34. Cicoira M., Rossi A., Bonapace S., et al. Effects of ACE gene insertion/deletion polymorphism on response to spironolactone in patients with chronic heart failure. Am J Med 2004, 116:657-661.
35. Foy C.A., Rice G.I., Ossei-Gerning N., Mansfield M.W., Grant P.J. Angiotensin-converting enzyme (ACE) gene polymorphisms in patients characterised by coronary angiography. Hum Genet 1997, 100:420-425.
36. Sethupathy P., Borel C., Gagnebin M., et al. Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3' untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am J Hum Genet 2007, 81:405-413.
37. White P.C., Slutsker L. Haplotype analysis of CYP11B2. Endocr Res 1995, 21:437-442.
38. Brand E., Kato N., Chatelain N., et al. Structural analysis and evaluation of the 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) gene in human essential hypertension. J Hypertens 1998, 16:1627-1633.
39. White P.C., Rainey W.E. Polymorphisms in CYP11B genes and 11-hydroxylase activity. J Clin Endocrinol Metab 2005, 90:1252-1255.
40. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens 2001, 14:186-194.
41. Paran E., Nemenoff R.A., Schrier R.W. Role of the renin-angiotensin system in essential hypertension. Curr Opin Nephrol Hypertens 1995, 4:295-299.
42. Mulatero P., Verhovez A., Morello F., Veglio F. Diagnosis and treatment of low-renin hypertension. Clin Endocrinol (Oxf) 2007, 67:324-334.
43. Bühler F.R., Bolli P., Kiowski W., Erne P., Hulthén U.L., Block L.H. Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients. Am J Med 1984, 77:36-42.
44. Laragh J.H. Modern system for treating high blood pressure based on renin profiling and vasoconstriction-volume analysis: a primary role for beta blocking drugs such as propranolol. Am J Med 1976, 61:797-810.
45. Turnbull F., Neal B., Pfeffer M., et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007, 25:951-958.
46. Brewster U.C., Perazella M.A. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 2004, 116:263-272.
47. Marchesi C., Paradis P., Schiffrin E.L. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci 2008, 29:367-374.
48. Schiffrin E.L. Beyond blood pressure: the endothelium and atherosclerosis progression. Am J Hypertens 2002, 15:115S-122S.
49. Mateo T., Abu Nabah Y.N., Abu Taha M., et al. Angiotensin II-induced mononuclear leukocyte interactions with arteriolar and venular endothelium are mediated by the release of different CC chemokines. J Immunol 2006, 176:5577-5586.
50. Schmidt-Ott K.M., Kagiyama S., Phillips M.I. The multiple actions of angiotensin II in atherosclerosis. Regul Pept 2000, 93:65-77.
51. Schieffer B., Schieffer E., Hilfiker-Kleiner D., et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000, 101:1372-1378.
52. Garnier A., Bendall J.K., Fuchs S., et al. Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 2004, 110:1819-1825.
53. Brown N.J., Kim K.S., Chen Y.Q., et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000, 85:336-344.
54. Rouleau J.L., Moyé L.A., de Champlain J., et al. Activation of neurohumoral systems following acute myocardial infarction. Am J Cardiol 1991, 68:80D-86D.
55. Rouleau J.L., Packer M., Moyé L., et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994, 24:583-591.
56. Montalescot G., Sechtem U., Achenbach S., et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013, 34:2949-3003.
57. Tomaschitz A., Pilz S., Ritz E., et al. Associations of plasma renin with 10-year cardiovascular mortality, sudden cardiac death, and death due to heart failure. Eur Heart J 2011, 32:2642-2649.
58. Emdin M., Passino C., Prontera C., et al. Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin Chem Lab Med 2004, 42:627-636.
59. Dzau V.J., Colucci W.S., Hollenberg N.K., Williams G.H. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981, 63:645-651.
60. Mehta P.K., Griendling K.K. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007, 292:C82-C97.
61. Nguyen G., Burcklé C.A., Sraer J.D. Renin/prorenin-receptor biochemistry and functional significance. Curr Hypertens Rep 2004, 6:129-132.
62. Shearer F., Lang C.C., Struthers A.D. Renin-angiotensin-aldosterone system inhibitors in heart failure. Clin Pharmacol Ther 2013, 94:459-467.
63. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012, 14:803-869.
64. Lee A.F., MacFadyen R.J., Struthers A.D. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur J Heart Fail 1999, 1:401-406.
65. Rousseau M.F., Gurné O., Duprez D., et al. Belgian RALES Investigators. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. J Am Coll Cardiol 2002, 40:1596-1601.
66. van de Wal R.M., Plokker H.W., Lok D.J., et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol 2006, 106:367-372.
67. Latini R., Masson S., Anand I., et al. Val-HeFT Investigators. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004, 25:292-299.
68. Masson S., Solomon S., Angelici L., et al. Val-Heft Investigators. Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail 2010, 16:964-970.
69. Vergaro G., Emdin M., Iervasi A., et al. Prognostic value of plasma renin activity in heart failure. Am J Cardiol 2011, 108:246-251.
70. Poletti R., Vergaro G., Zyw L., Prontera C., Passino C., Emdin M. Prognostic value of plasma renin activity in heart failure patients with chronic kidney disease. Int J Cardiol 2013, 167:711-715.
71. Guder G., Bauersachs J., Frantz S., et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 2007, 115:1754-1761.
72. Vergaro G., Fatini C., Sticchi E., et al. Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism. J Cardiovasc Med (Hagerstown) Jul 17 2014, [Epub ahead of print, PubMed PMID: 25036270].
73. Campbell D.J., Nussberger J., Stowasser M., et al. Activity assays and immunoassays for plasma renin and prorenin: information provided and precautions necessary for accurate measurement. Clin Chem 2009, 55:867-877.
74. Zucchelli G.C., Malvano R., Rosa U., Salvetti A. Control of the enzyme systems in plasma renin activity measurement by angiotensin I radioimmunoassay. J Nucl Biol Med 1973, 17:187-195.
75. Schalekamp M.A., Derkx F.H., Deinum J., Danser A.J. Newly developed renin and prorenin assays and the clinical evaluation of renin inhibitors. J Hypertens 2008, 26:928-937.
76. Derkx F.H., Schalekamp M.P., Schalekamp M.A. Two-step prorenin-renin conversion. Isolation ofan intermediary form of activated prorenin. J Biol Chem 1987, 262:2472-2477.
77. Nussberger J., Wuerzner G., Jensen C., Brunner H.R. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 2002, 39:e1-e8.
78. Picard C., Ronco P., Moullier P., et al. Epitope diversity of angiotensin II analysed with monoclonal antibodies. Immunology 1986, 57:19-24.
79. Lambert D.W., Clarke N.E., Turner A.J. Not just angiotensinases: new roles for the angiotensin-converting enzymes. Cell Mol Life Sci 2010, 67:89-98.
80. Simon D., Romestand B., Huang H., et al. Direct, simplified, and sensitive assay of angiotensin II in plasma extracts performed with a high-affinity monoclonal antibody. Clin Chem 1992, 38:1963-1967.
81. López J.M., Redondo M., Téllez T., Morell M. A sensitive enzyme immunoassay for angiotensin II in serum. J Pharm Biomed Anal 1994, 12:1411-1416.
82. Williams G.H. Aldosterone biosynthesis, regulation, and classical mechanism of action. Heart Fail Rev 2005, 10:7-13.
83. Bayard F., Beitins I., Kowarski A., Migeaon C. Measurement of plasma aldosterone by radioimmunoassay. J Clin Endocrinol Metab 1970, 31:1-6.
84. Miller M., Sagnella G., MacGregor G. Extraction method and nonextracted kit method compared for measuring plasma aldosterone. Clin Chem 1997, 43:1995-1997.
85. Schirpenbach C., Seiler L., Maser-Gluth C., Beuschlein F., Reincke M., Bidlingmaier M. Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassays with and without extraction steps. Clin Chem 2006, 52:1749-1755.
86. Manolopoulou J., Mulatero P., Maser-Gluthc C., et al. Saliva as a medium for aldosterone measurement in repeated sampling studies. Steroids 2009, 853-858.
87. Walsh P.R., Wang M.C., Turner E.A. Non-chromatographic radioimmunoassay procedure for urinary aldosterone. Clin Chem 1979, 25:1226-1229.
88. Al-Dujaili E.A., Edwards C.R. Development and application of a simple radioimmunoassay for urinary aldosterone. Clin Chim Acta 1981, 116:277-287.
89. Stöckl D., Reinauer H., Thienpont L.M., De Leenheer A.P. Determination of aldosterone in human serum by isotope dilution gas chromatography/mass spectrometry using a new heptafluorobutyryl derivative. Biol Mass Spectrom 1991, 20:657-664.
90. Thienpont L.M., Van Nieuwenhove B., Stöckl D., Reinauer H., De Leenheer A.P. Determination of reference method values by isotope dilution-gas chromatography/mass spectrometry: a five years' experience of two European Reference Laboratories. Eur J Clin Chem Clin Biochem 1996, 34:853-860.
91. Taylor P.J., Cooper P.D., Gordon R.D., Stowasser M. Measurement of aldosterone in human plasma by semiautomated HPLC-tandem mass spectrometry. Clin Chem 2009, 55:1155-1162.
92. Funder J.W., Carey R.M., Fardella C., et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008, 93:3266-3281.
93. Rousseau M.F., Gurné O., Duprez D., et al. Belgian RALES Investigators. Beneficial neurohormonal profile ospironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. J Am Coll Cardiol 2002, 40:1596-1601.
94. Weber K.T. Aldosteronism revisited: perspectives on less well recognized actions of aldosterone. J Lab Clin Med 2003, 142:71-82.
95. Levy W.C., Mozaffarian D., Linker D.T., et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006, 113:1424-1433.
96. Clerico A., Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 2004, 50:33-50.
97. Pitt B. 'Escape' of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995, 9:145-149.
98. Schrier R.W. Aldosterone 'escape' vs 'breakthrough'. Nat Rev Nephrol 2010, 6:61.
99. McMurray J.J., Pitt B., Latini R., et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008, 1:17-24.
100. Yamaji M., Tsutamoto T., Kawahara C., et al. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(c) levels in patients with chronic heart failure. Am Heart J 2010, 160:915-921.
101. Mentz R.J., Bakris G.L., Waeber B., et al. The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol 2013, 167:1677-1687.
102. McMurray J.J., Ostergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767-771.
103. Krum H., Carson P., Farsang C., et al. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail 2004, 6:937-945.
104. McNamara D.M., Holubkov R., Postava L., et al. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol 2004, 44:2019-2026.